Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Increasing Patient Involvement In Drug Development

Authors: Maria M. Lowe, PharmD, BCPS, David A. Blaser, PharmD, Lisa Cone, BA, Steve Arcona, PhD, John Ko, PharmD, MS, Rahul Sasane, PhD, Paul Wicks, PhD

Abstract:

Background

To ensure the creation of treatments that maximize value at the lowest cost, all aspects of the health care system need to align with patient needs and preferences. Despite growing efforts to engage patients in research and regulatory activities, the pharmaceutical industry has yet to maximize patient involvement in the drug development process.

Objective

To gain a better understanding of the present state of patient involvement in drug development.

Methods

Through a semistructured interview methodology, we sought to identify opportunities, barriers, and examples of patient involvement in the drug development process. Telephone interviews were conducted with six senior leaders of evidence generation within the pharmaceutical industry and four patients. These interviews were supplemented with interviews with a research funder, a regulator, a patient advocacy group, and a caregiver.

Results

Although our interviewees spoke of the potential benefits of aligning research around the needs of patients, there were few examples they could share to suggest this was occurring at scale. A number of barriers were identified including the added burden associated with adverse event reporting, concerns about patient representativeness or their ability to participate in drug development conversations, and the costs in time and resources involved relative to returns on investment.

Conclusions

As health care systems continue to evolve and establish patients as the primary stakeholder in their health care decision making, the pharmaceutical industry will need to be innovative to demonstrate the value of their products relative to the outcomes experienced by patients. Pharmaceutical companies should recognize the value of involving patients across the entire product life cycle and work to transform present perceptions and practices throughout their organizations.

Keywords

decision making; drug development; methodology; patient-centered

Citation: Maria M. Lowe, PharmD, BCPS, David A. Blaser, PharmD, Lisa Cone, BA, Steve Arcona, PhD, John Ko, PharmD, MS, Rahul Sasane, PhD, Paul Wicks, PhD Increasing Patient Involvement In Drug Development doi:10.1016/j.jval.2016.04.009

Availableonline: 24 May 2016

Copyright: © 2016, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/).http://dx.doi.org/10.1016/j.jval.2016.04.00

Acknowledgments

We thank the interviewees and patients for their time and leadership in helping us better understand how to incorporate the patient perspective in the development process for new medications.

Source of financial support: This work was funded by Novartis Pharmaceuticals. No restrictions were placed on the design, analysis, or interpretation of the research or on the writing and submission of the manuscript. The views expressed in this publication are those of the authors.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024